[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341729-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341729-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","overexpression-of-ccl-20-and-cxcl-8-genes-enhances-tumor-escape-and-resistance-to-cemiplimab-a-programmed-cell-death-protein-1-pd-1-inhibitor","Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor","","Cemiplimab shows clinical activity in cutaneous squamous cell carcinoma (cSCC), yet mechanisms underlying primary and acquired resistance remain unclear. Clinical data were collected from locally advanced and/or metastatic cSCC patients treated with cemiplimab across two Italian university centers, and Nanostring-based gene expression profiling of 770 cancer/immune genes was performed on 20 tumor samples. Among 81 patients (median age 82), 16.4-month follow-up yielded 12/24-month PFS of 53%/42% and 12/24-month OS of 71%/61%. Overall response rate was 58% with disease control rate 77.8%, and treatment was well tolerated. Responder and non-responder tumors differed substantially, especially in immune-regulation genes; cemiplimab-resistant tumors showed overexpression of CCL-20 and CXCL-8, suggesting potential biomarkers for lack of response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/overexpression-of-ccl-20-and-cxcl-8-genes-enhances-tumor-escape-and-resistance-to-cemiplimab-a-programmed-cell-death-protein-1-pd-1-inhibitor/341729/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/overexpression-of-ccl-20-and-cxcl-8-genes-enhances-tumor-escape-and-resistance-to-cemiplimab-a-programmed-cell-death-protein-1-pd-1-inhibitor/341729.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about cemiplimab in cSCC?","Question",{"text":63,"@type":64},"The study investigates mechanisms of primary and acquired resistance to cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma, focusing on potential biomarkers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were biomarkers explored in this research?",{"text":68,"@type":64},"Gene expression analysis using a Nanostring Technologies platform evaluated 770 cancer- and immune-related genes on tumor tissue samples from responders and nonresponders.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genes were linked to cemiplimab resistance?",{"text":72,"@type":64},"Cemiplimab-resistant tumors were associated with overexpression of CCL-20 and CXCL-8, which may serve as biomarkers for lack of response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341729,1790488064,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","ONCOIMMUNOLOGY  \n2024, VOL. 13, NO. 1, 2388315 [https://doi.org/10.1080/2162402X.2024.2388315](https://doi.org/10.1080/2162402X.2024.2388315)  \nORIGINAL RESEARCH     \nOverexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma  \nVincenzo De Falco a*, Stefania Napolitano a*, Renato Francob, Federica Zito Marinob, Luigi Formisanoc, Daniela Espositoc, Gabriella Suaratoa, Rossella Napolitanoa, Alfonso Espositoa, Francesco Caragliaa,  \nMaria Cristina Giuglianoa, Eleonora Ciolia, Vincenzo Famigliettia, Roberto Biancoc, Giuseppe Argenzianod, Andrea Ronchib, Davide Ciardielloa,e, Valerio Nardonef, Emma D’Ippolitof, Sara Del Tufof, Fortunato Ciardielloa, and Teresa Troiani a  \naMedical Oncology Unit, Department of Precision Medicine, Università della Campania “Luigi Vanvitelli”, Naples, Italy; bPathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, via Luciano Armanni, Naples, Italy; cDepartment of Clinical Medicine and Surgery, University of Naples “Federico II”, Napoli, Italy; dDermatology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy; eDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy; fRadiology Unit, Department of Precision Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy  \nABSTRACT  \nCemiplimab has demonstrated relevant clinical activity in cutaneous squamous cell carcinoma (cSCC) but mechanisms of primary and acquired resistance to immunotherapy are still unknown. We collected clinical data from locally advanced and/or metastatic cSSC patients treated with cemiplimab in two Italian University centers. In addition, gene expression analysis by using Nanostring Technologies platform to evaluate 770 cancer-and immune-related genes on 20 tumor tissue samples (9 responders and 11 nonresponders to cemiplimab) was performed. We enrolled 81 patients with a median age of 82 years. After 16.4 months of median follow-up, 12-and 24-months PFS were 53% and 42%, respectively; while 12-and 24-months OS were 71% and 61%, respectively. Treatment was well tolerated. Overall response rate (ORR) was 58%, with a disease control rate (DCR) of 77.8% . The difference between genes expressed in responder versus non-responder patient samples was substantial, particularly for genes involved in immune system regulation. Cemiplimab-resistant tumors were associated with over-expression of CCL- 20 and CXCL-8 . Cemiplimab confirmed efficacy and safety data in real-life cSCC patients. Overexpression of CCL-20 and CXCL-8 could represent biomarkers of lack of response to immunotherapy.  \nARTICLE HISTORY  \nReceived 28 March 2024 Revised 29 July 2024 Accepted 31 July 2024  \nKEYWORDS  \nCemiplimab; cSCC; cutaneous squamous cell carcinoma; gene expression profiling; immunotherapy; nanostring; real-world data  \nBackground  \nCutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer, which is typically observed in elderly patients with a clinical history of chronic sun exposure. 1 Its incidence has increased in recent decades and, if early treated with surgery, the 5-year cure rate is over 90% . 1 Ina minority of cases, due to patient neglect or to the aggressiveness of the disease, it is diagnosed in locally advanced (lacSCC) or metastatic (mcSCC) stages. Due to the peculiar evolution of this tumor and its clinical presentation, staging is quite complex. In fact, the definition of lacSCC is not well defined, by including tumors that cannot be cured with surgery, radiation therapy (RT), or by a combination of the two treatments. 1 Until a few years ago, for these subgroups of patients, t","cbCaihZAREMbc5Uf","https://ap.wps.com/l/cbCaihZAREMbc5Uf","pdf",4964486,11,"English","# Abstract\n## Background\n## Methods and gene expression profiling\n## Results and survival outcomes\n## Resistance mechanisms and biomarker implications","[{\"question\":\"What question does the study address about cemiplimab in cSCC?\",\"answer\":\"The study investigates mechanisms of primary and acquired resistance to cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma, focusing on potential biomarkers.\"},{\"question\":\"How were biomarkers explored in this research?\",\"answer\":\"Gene expression analysis using a Nanostring Technologies platform evaluated 770 cancer- and immune-related genes on tumor tissue samples from responders and nonresponders.\"},{\"question\":\"Which genes were linked to cemiplimab resistance?\",\"answer\":\"Cemiplimab-resistant tumors were associated with overexpression of CCL-20 and CXCL-8, which may serve as biomarkers for lack of response.\"}]","Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor | PDF",1790043421,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/393d045388ceb11bc0db7e50acadce8b.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/944b6c0c0ded79517fe2d413172170d1.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfb9920ad0ed2ad6b9ab1bbbbd4d286c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9481e2f759575678d3f87a80d93aee3.webp",980,1306]